Global Non-invasive Prenatal Testing Market 2017-2021

  • ID: 4424995
  • Report
  • Region: Global
  • 86 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Agilent Technologies
  • Berry Genomics
  • BGI Genomics
  • F. Hoffman-La Roche
  • Illumina
  • LifeCodexx
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Non-invasive Prenatal Testing

Non-invasive prenatal screening is performed primarily by ultrasonography and serum testing from maternal plasma. Ultrasonography uses the clear tissue behind the infant’s neck to detect genetic defects. A fetus with abnormalities tends to accumulate more fluid. Hence, more clear space is detected behind the neck, which is an indicative measure. Maternal serum screening is a method that involves blood testing in the first and second trimester of the gestation period where specific chemicals such as pregnancy-associated plasma protein A (PAPP-A) and free beta human chorionic gonadotropin (HCG) are checked.

The analysts forecast the global non-invasive prenatal testing market to grow at a CAGR of 16.86% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global non-invasive prenatal testing market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Non-invasive Prenatal Testing Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • BGI Genomics
  • Illumina
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics
Other prominent vendors
  • Agilent Technologies
  • Berry Genomics
  • F. Hoffman-La Roche
  • LifeCodexx
  • Natera
  • PerkinElmer
Market drivers
  • Advantages of non-invasive methods over invasive methods
  • For a full, detailed list, view the full report
Market challenges
  • Abortion rate and ethical hurdles
  • For a full, detailed list, view the full report
Market trends
  • Increase in acceptance of NIPT
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Agilent Technologies
  • Berry Genomics
  • BGI Genomics
  • F. Hoffman-La Roche
  • Illumina
  • LifeCodexx
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Overview
PART 05: MARKET LANDSCAPE
  • Overview
  • Market size and forecast
  • Five forces analysis
PART 06: SEGMENTATION BY APPLICATION
  • Overview
  • Trisomy
  • Microdeletions
  • Others
PART 07: SEGMENTATION BY END-USER
  • Overview
  • Diagnostic centers
  • Hospitals
PART 08: SEGMENTATION BY GEOGRAPHY
  • Overview
  • Regional comparison
  • NIPT market in Americas
  • NIPT market in EMEA
  • NIPT market in APAC
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increase in acceptance of NIPT
  • Increase in genetic counseling
  • Growth of genetic screening programs at births
PART 12: VENDOR LANDSCAPE
  • Competitive scenario
  • Investment opportunities
PART 13: KEY VENDOR ANALYSIS
  • BGI Genomics
  • Illumina
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics
  • Other prominent vendors
PART 14: APPENDIX
  • List of abbreviations
LIST OF EXHIBITS
Exhibit 01: Types of prenatal diagnosis and screening
Exhibit 02: Lifecycle of prenatal testing techniques
Exhibit 03: Comparative analysis of NIPT with other techniques
Exhibit 04: Global NIPT market: Overview 2017-2021
Exhibit 05: Global NIPT market 2016-2021 ($ millions)
Exhibit 06: Five forces analysis
Exhibit 07: Global NIPT market: Segmentation by application 2016 (% share)
Exhibit 08: Global NIPT market: Segmentation by application 2021 (% share)
Exhibit 09: Global NIPT market: Segmentation by application 2016-2021 (% share)
Exhibit 10: Global NIPT by trisomy market 2016-2021 ($ millions)
Exhibit 11: Global NIPT by microdeletions market 2016-2021 ($ millions)
Exhibit 12: Global NIPT by others market 2016-2021 ($ millions)
Exhibit 13: Global NIPT market: Segmentation by end-user 2016-2021 (% share)
Exhibit 14: Global NIPT market by diagnostic centers 2016-2021 ($ millions)
Exhibit 15: Global NIPT market by hospitals 2016-2021 ($ millions)
Exhibit 16: Global NIPT market: Segmentation by geography 2016-2021 (% share)
Exhibit 17: Global NIPT market: Regional comparison
Exhibit 18: NIPT market in Americas 2016-2021($ millions)
Exhibit 19: NIPT market in Americas: Year-over-year growth 2017-2021 (%)
Exhibit 20: NIPT market in EMEA 2016-2021 ($ millions)
Exhibit 21: NIPT market in EMEA: Year-over-year growth (%) (2017-2021)
Exhibit 22: NIPT market in APAC 2016-2021 ($ million)
Exhibit 23: NIPT market in APAC: Year-over-year growth 2017-2021 (%)
Exhibit 24: Global NIPT market: Key leading countries
Exhibit 25: Global NIPT market: Growth and success factors of vendors
Exhibit 26: Global NIPT market: Investment opportunity mapping
Exhibit 27: BGI Genomics: Overview
Exhibit 28: BGI Genomics: Strength analysis
Exhibit 29: BGI Genomics: Strategy assessment
Exhibit 30: BGI Genomics opportunity assessment
Exhibit 31: Illumina: Overview
Exhibit 32: Illumina: Strength analysis
Exhibit 33: Illumina: Strategy assessment
Exhibit 34: Illumina: Opportunity assessment
Exhibit 35: Laboratory Corporation of America Holdings: Overview
Exhibit 36: Laboratory Corporation of America Holdings: Strength analysis
Exhibit 37: Laboratory Corporation of America Holdings: Strategy assessment
Exhibit 38: Laboratory Corporation of America Holdings: Opportunity assessment
Exhibit 39: Quest Diagnostics Overview
Exhibit 40: Quest Diagnostics: Strength analysis
Exhibit 41: Quest Diagnostics: Strategy assessment
Exhibit 42: Quest Diagnostics: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Agilent Technologies
  • Berry Genomics
  • BGI Genomics
  • F. Hoffman-La Roche
  • Illumina
  • LifeCodexx
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: - Global Non-invasive Prenatal Testing Market 2017-2021

The author of the report recognizes the following companies as the key players in the global non-invasive prenatal testing market: BGI Genomics, Illumina, Laboratory Corporation of America Holdings, and Quest Diagnostics.

Other Prominent Vendors in the market are: Agilent Technologies, Berry Genomics, F. Hoffman-La Roche, LifeCodexx, Natera, and PerkinElmer.

Commenting on the report, an analyst from the research team said: “One trend in the market is increase in acceptance of NIPT. The clinical implementation of NIPT is increasing across the world due to its commercialization and the marketing capabilities of vendors. Within a very short span of time, NIPT has been adopted by physicians across the world. Most physicians include NIPT for routine pregnancy diagnosis.”

According to the report, one driver in the market is advantages of non-invasive methods over invasive methods. The introduction of NIPT in 2011 enabled the safe screening and detection of chromosomal abnormalities in fetuses. Invasive methods of prenatal testing are painful. They could also cause miscarriages. However, advances in genomic sciences and bioinformatic analytical tools have led to the development of NIPT. NIPT reduces the chances of miscarriage, involves less pain, and reduces the number of false-positive results. The fetus is not affected because the fetal DNA used for screening is collected from maternal blood and tested using sequencing.

Further, the report states that one challenge in the market is abortion rate and ethical hurdles. With a rapid increase in prenatal screening using NIPT, there are chances of early fetal abortions. NIPT is widely used to detect genetic defects. However, it is also used to determine the gender of the fetus, which could lead to the termination of pregnancy. Choice about the future of the child, physical and emotional harm to the mother, and societal views are ethical challenges associated with prenatal screening.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

  • BGI Genomics
  • Illumina
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics
  • Agilent Technologies
  • Berry Genomics
  • F. Hoffman-La Roche
  • LifeCodexx
  • Natera
  • PerkinElmer
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll